
Shuhua Tan

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4785827/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. EBioMedicine, 2021, 65, 103250.	6.1	11
2	Generation of a Novel High-Affinity Antibody Binding to PCSK9 Catalytic Domain with Slow Dissociation Rate by CDR-Grafting, Alanine Scanning and Saturated Site-Directed Mutagenesis for Favorably Treating Hypercholesterolemia. Biomedicines, 2021, 9, 1783.	3.2	1
3	Hsa-miR-140-5p down-regulates LDL receptor and attenuates LDL-C uptake in human hepatocytes. Atherosclerosis, 2020, 297, 111-119.	0.8	20
4	Lunasin Improves the LDL-C Lowering Efficacy of Simvastatin via Inhibiting PCSK9 Expression in Hepatocytes and ApoEâ^'/â^' Mice. Molecules, 2019, 24, 4140.	3.8	7
5	Lunasin attenuates oxidantâ€induced endothelial injury and inhibits atherosclerotic plaque progression in ApoE ^{â^'/â^'} mice by upâ€regulating heme oxygenaseâ€1 <i>via</i> PI3K/Akt/Nrf2/ARE pathway. FASEB Journal, 2019, 33, 4836-4850.	0.5	34
6	Combination of novel DR5 targeting agonistic scFv antibody TR2-3 with cisplatin shows enhanced synergistic antitumor activity in vitro and in vivo. Biomedicine and Pharmacotherapy, 2018, 98, 271-279.	5.6	4
7	Hirudin as a novel fusion tag for efficient production of lunasin in Escherichia coli. Preparative Biochemistry and Biotechnology, 2017, 47, 619-626.	1.9	6
8	A Novel Fully Human Agonistic Single Chain Fragment Variable Antibody Targeting Death Receptor 5 with Potent Antitumor Activity In Vitro and In Vivo. International Journal of Molecular Sciences, 2017, 18, 2064.	4.1	9
9	Lunasin functionally enhances LDL uptake via inhibiting PCSK9 and enhancing LDLR expression <i>in vitro</i> and <i>in vivo</i> . Oncotarget, 2017, 8, 80826-80840.	1.8	22